Loading...
Loading...
ALZN| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 5.3K |
| Gross Profit | -5.3K |
| Operating Expense | 5,423.5K |
| Operating I/L | -5,423.5K |
| Other Income/Expense | -2.1K |
| Interest Income | 0.0K |
| Pretax | -5,425.6K |
| Income Tax Expense | 2.1K |
| Net Income/Loss | -5,427.6K |
Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical company specializing in the development of products for the treatment of neurodegenerative and psychiatric disorders. Their pipeline includes AL001, a Phase II clinical trial product delivering a therapeutic combination for Alzheimer's, bipolar disorder, PTSD, major depressive disorder, and other neurodegenerative and psychiatric disorders. Additionally, AL002, which completed the preclinical stage, uses a method employing a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the patient's immunological system to combat Alzheimer's disease.
